129 related articles for article (PubMed ID: 10534306)
1. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.
Ward KW; Azzarano LM; Bondinell WE; Cousins RD; Huffman WF; Jakas DR; Keenan RM; Ku TW; Lundberg D; Miller WH; Mumaw JA; Newlander KA; Pirhalla JL; Roethke TJ; Salyers KL; Souder PR; Stelman GJ; Smith BR
Drug Metab Dispos; 1999 Nov; 27(11):1232-41. PubMed ID: 10534306
[TBL] [Abstract][Full Text] [Related]
2. Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations.
Ward KW; Azzarano LM; Evans CA; Smith BR
Xenobiotica; 2004 Apr; 34(4):353-66. PubMed ID: 15268980
[TBL] [Abstract][Full Text] [Related]
3. Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling.
Feng MR; Loo J; Wright J
Drug Metab Dispos; 1998 Oct; 26(10):982-8. PubMed ID: 9763403
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
5. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans.
Yamazaki S; Toth LN; Black ML; Duncan JN
Drug Metab Dispos; 2004 Apr; 32(4):398-404. PubMed ID: 15039292
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters.
Hayakawa H; Fukushima Y; Kato H; Fukumoto H; Kadota T; Yamamoto H; Kuroiwa H; Nishigaki J; Tsuji A
Drug Metab Dispos; 2003 Nov; 31(11):1409-18. PubMed ID: 14570774
[TBL] [Abstract][Full Text] [Related]
9. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.
Ward KW; Smith BR
Drug Metab Dispos; 2004 Jun; 32(6):603-11. PubMed ID: 15155551
[TBL] [Abstract][Full Text] [Related]
11. Disposition of (5H-dibenzo [a,d]cyclohepten-5-ylidene)acetic acid in laboratory animals.
Schillings RT; Sisenwine SF
Drug Metab Dispos; 1986; 14(4):405-12. PubMed ID: 2873986
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
13. Formation and protein binding of the acyl glucuronide of a leukotriene B4 antagonist (SB-209247): relation to species differences in hepatotoxicity.
Kenny JR; Maggs JL; Tettey JN; Harrell AW; Parker SG; Clarke SE; Park BK
Drug Metab Dispos; 2005 Feb; 33(2):271-81. PubMed ID: 15523047
[TBL] [Abstract][Full Text] [Related]
14. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D
Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742
[TBL] [Abstract][Full Text] [Related]
15. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.
Pavankuamr VV; Vinu CA; Mullangi R; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2007; 32(1):29-37. PubMed ID: 17479541
[TBL] [Abstract][Full Text] [Related]
17. Interspecies scaling and comparisons in drug development and toxicokinetics.
Ings RM
Xenobiotica; 1990 Nov; 20(11):1201-31. PubMed ID: 2275215
[TBL] [Abstract][Full Text] [Related]
18. Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR.
Morris ME; Yang X; Gandhi YA; Bhansali SG; Benincosa LJ
Biopharm Drug Dispos; 2012 Jan; 33(1):1-14. PubMed ID: 22170504
[TBL] [Abstract][Full Text] [Related]
19. Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Shim HJ; Kim YC; Lee JH; Kwon JW; Kim WB; Kim YG; Kim SH; Lee MG
Biopharm Drug Dispos; 2005 Oct; 26(7):269-77. PubMed ID: 15991256
[TBL] [Abstract][Full Text] [Related]
20. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys.
Prakash C; Johnson KA; Schroeder CM; Potchoiba MJ
Drug Metab Dispos; 2008 Sep; 36(9):1753-69. PubMed ID: 18515329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
